William Blair Issues Pessimistic Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at William Blair cut their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a research note issued on Tuesday, October 29th. William Blair analyst M. Kaczor now anticipates that the medical research company will earn $0.59 per share for the quarter, down from their previous estimate of $0.64. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.61 per share. William Blair also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.63 EPS, Q3 2025 earnings at $0.61 EPS, Q4 2025 earnings at $0.63 EPS and FY2025 earnings at $2.46 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share.

A number of other analysts have also recently commented on the company. Barclays dropped their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Bank of America cut shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Sixteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Trading Up 1.2 %

NYSE:EW opened at $69.37 on Wednesday. The firm has a market capitalization of $41.80 billion, a P/E ratio of 29.90, a PEG ratio of 3.00 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company’s 50-day simple moving average is $68.10 and its 200 day simple moving average is $77.99.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of EW. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 1.1% in the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after buying an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd lifted its holdings in shares of Edwards Lifesciences by 17.8% in the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock worth $216,013,000 after buying an additional 494,604 shares in the last quarter. Finally, Champlain Investment Partners LLC boosted its position in shares of Edwards Lifesciences by 3.1% during the first quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after acquiring an additional 88,205 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.